Eaton Vance Management’s West Pharmaceutical WST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
$44.5M Buy
180,971
+81,234
+81% +$24.7M 0.07% 286
2022
Q2
$30.2M Sell
99,737
-1,149
-1% -$374K 0.04% 376
2022
Q1
$41.4M Buy
100,886
+30,532
+43% +$12M 0.05% 348
2021
Q4
$33M Buy
70,354
+992
+1% +$427K 0.04% 380
2021
Q3
$28.8M Buy
69,362
+2,666
+4% +$1.12M 0.04% 366
2021
Q2
$23.9M Buy
66,696
+5,879
+10% +$1.94M 0.03% 417
2021
Q1
$17.1M Buy
60,817
+2,142
+4% +$613K 0.03% 462
2020
Q4
$16.6M Buy
58,675
+2,436
+4% +$684K 0.03% 446
2020
Q3
$15.5M Buy
56,239
+1,636
+3% +$433K 0.03% 409
2020
Q2
$12.4M Buy
54,603
+3,280
+6% +$644K 0.03% 413
2020
Q1
$7.81M Sell
51,323
-3,253
-6% -$501K 0.02% 461
2019
Q4
$8.2M Sell
54,576
-27
-0% -$3.93K 0.02% 501
2019
Q3
$7.74M Sell
54,603
-49,690
-48% -$6.84M 0.02% 499
2019
Q2
$13.1M Sell
104,293
-14,788
-12% -$1.75M 0.03% 382
2019
Q1
$13.1M Sell
119,081
-116,461
-49% -$12.1M 0.03% 359
2018
Q4
$23.1M Sell
235,542
-30,316
-11% -$3.29M 0.06% 250
2018
Q3
$32.8M Sell
265,858
-6,067
-2% -$680K 0.07% 229
2018
Q2
$27M Sell
271,925
-323,717
-54% -$29.8M 0.06% 247
2018
Q1
$52.6M Buy
595,642
+307,411
+107% +$28.8M 0.07% 242
2017
Q4
$28.4M Sell
288,231
-14,314
-5% -$1.4M 0.07% 233
2017
Q3
$29.1M Sell
302,545
-6,183
-2% -$559K 0.08% 219
2017
Q2
$29.2M Buy
308,728
+17,512
+6% +$1.61M 0.08% 216
2017
Q1
$23.8M Buy
291,216
+102,473
+54% +$8.57M 0.06% 230
2016
Q4
$16M Buy
188,743
+5,352
+3% +$421K 0.05% 258
2016
Q3
$13.7M Sell
183,391
-80,409
-30% -$6.38M 0.04% 264
2016
Q2
$20M Sell
263,800
-103,851
-28% -$7.56M 0.06% 222
2016
Q1
$25.5M Sell
367,651
-738
-0.2% -$44.4K 0.08% 193
2015
Q4
$22.2M Sell
368,389
-8,098
-2% -$487K 0.07% 209
2015
Q3
$20.4M Sell
376,487
-18,540
-5% -$1.08M 0.06% 221
2015
Q2
$22.9M Sell
395,027
-28,195
-7% -$1.57M 0.07% 212
2015
Q1
$25.5M Sell
423,222
-10,164
-2% -$542K 0.08% 194
2014
Q4
$23.1M Sell
433,386
-22,987
-5% -$1.15M 0.07% 208
2014
Q3
$20.4M Buy
456,373
+7,134
+2% +$303K 0.06% 221
2014
Q2
$18.9M Buy
449,239
+411,687
+1,096% +$17.6M 0.06% 227
2014
Q1
$1.65M Sell
37,552
-11,961
-24% -$563K ﹤0.01% 568
2013
Q4
$2.43M Sell
49,513
-36,724
-43% -$1.72M 0.01% 492
2013
Q3
$3.55M Sell
86,237
-985
-1% -$37.6K 0.01% 415
2013
Q2
$3.06M Buy
+87,222
New +$2.87M 0.01% 417

Other funds holding WST

Eaton Vance Management's WST Position: Q3 2022 in Review

Eaton Vance Management increased its West Pharmaceutical (WST) stake by 81% in Q3 2022, buying an estimated $24.7M and bringing the position to 180,971 shares worth $44.5M. The position accounts for 0.07% of the portfolio, ranked #286.

Eaton Vance Management first reported a position in WST in Q2 2013 and has held it in 38 quarters since. The position peaked at $52.6M in Q1 2018. 638 funds tracked by Wall St. Rank hold WST as of Q3 2022.

  • Eaton Vance Management held 180,971 shares of West Pharmaceutical worth $44.5M as of Q3 2022.
  • Eaton Vance Management bought 81,234 West Pharmaceutical shares in Q3 2022, an estimated $24.7M.
  • West Pharmaceutical made up 0.07% of Eaton Vance Management's portfolio in Q3 2022, its #286 holding.
  • Eaton Vance Management first reported a position in West Pharmaceutical in Q2 2013 and has held it in 38 quarters since.
  • Eaton Vance Management's West Pharmaceutical position peaked at $52.6M in Q1 2018.
  • 638 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.